arachidonyltrifluoromethane and iberiotoxin

arachidonyltrifluoromethane has been researched along with iberiotoxin* in 2 studies

Other Studies

2 other study(ies) available for arachidonyltrifluoromethane and iberiotoxin

ArticleYear
Cytochrome P-450 metabolites of 2-arachidonoylglycerol play a role in Ca2+-induced relaxation of rat mesenteric arteries.
    American journal of physiology. Heart and circulatory physiology, 2008, Volume: 294, Issue:5

    The perivascular sensory nerve (PvN) Ca(2+)-sensing receptor (CaR) is implicated in Ca(2+)-induced relaxation of isolated, phenylephrine (PE)-contracted mesenteric arteries, which involves the vascular endogenous cannabinoid system. We determined the effect of inhibition of diacylglycerol (DAG) lipase (DAGL), phospholipase A(2) (PLA(2)), and cytochrome P-450 (CYP) on Ca(2+)-induced relaxation of PE-contracted rat mesenteric arteries. Our findings indicate that Ca(2+)-induced vasorelaxation is not dependent on the endothelium. The DAGL inhibitor RHC 802675 (1 microM) and the CYP and PLA(2) inhibitors quinacrine (5 microM) (EC(50): RHC 802675 2.8 +/- 0.4 mM vs. control 1.4 +/- 0.3 mM; quinacrine 4.8 +/- 0.4 mM vs. control 2.0 +/- 0.3 mM; n = 5) and arachidonyltrifluoromethyl ketone (AACOCF(3), 1 microM) reduced Ca(2+)-induced relaxation of mesenteric arteries. Synthetic 2-arachidonoylglycerol (2-AG) and glycerated epoxyeicosatrienoic acids (GEETs) induced concentration-dependent relaxation of isolated arteries. 2-AG relaxations were blocked by iberiotoxin (IBTX) (EC(50): control 0.96 +/- 0.14 nM, IBTX 1.3 +/- 0.5 microM) and miconazole (48 +/- 3%), and 11,12-GEET responses were blocked by IBTX (EC(50): control 55 +/- 9 nM, IBTX 690 +/- 96 nM) and SR-141716A. The data suggest that activation of the CaR in the PvN network by Ca(2+) leads to synthesis and/or release of metabolites of the CYP epoxygenase pathway and metabolism of DAG to 2-AG and subsequently to GEETs. The findings indicate a role for 2-AG and its metabolites in Ca(2+)-induced relaxation of resistance arteries; therefore this receptor may be a potential target for the development of new vasodilator compounds for antihypertensive therapy.

    Topics: 8,11,14-Eicosatrienoic Acid; Acetylcholine; Animals; Arachidonic Acids; Calcium; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Endocannabinoids; Enzyme Inhibitors; Glycerides; Lipoprotein Lipase; Male; Mesenteric Arteries; Miconazole; Peptides; Phenylephrine; Phospholipase A2 Inhibitors; Phospholipases A2; Piperidines; Potassium Channel Blockers; Potassium Channels, Calcium-Activated; Pyrazoles; Quinacrine; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptors, Calcium-Sensing; Rimonabant; Signal Transduction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents

2008
The cellular mechanisms by which adenosine evokes release of nitric oxide from rat aortic endothelium.
    The Journal of physiology, 2006, Jan-01, Volume: 570, Issue:Pt 1

    Adenosine and nitric oxide (NO) are important local mediators of vasodilatation. The aim of this study was to elucidate the mechanisms underlying adenosine receptor-mediated NO release from the endothelium. In studies on freshly excised rat aorta, second-messenger systems were pharmacologically modulated by appropriate antagonists while a NO-sensitive electrode was used to measure adenosine-evoked NO release from the endothelium. We showed that A1-mediated NO release requires extracellular Ca2+, phospholipase A2 (PLA2) and ATP-sensitive K+ (KATP) channel activation whereas A2A-mediated NO release requires extracellular Ca2+ and Ca2+-activated K+ (KCa) channels. Since our previous study showed that A1- and A2A-receptor-mediated NO release requires activation of adenylate cyclase (AC), we propose the following novel pathways. The K+ efflux resulting from A1-receptor-coupled KATP-channel activation facilitates Ca2+ influx which may cause some stimulation of endothelial NO synthase (eNOS). However, the increase in [Ca2+]i also stimulates PLA2 to liberate arachidonic acid and stimulate cyclooxygenase to generate prostacyclin (PGI2). PGI2 acts on its endothelial receptors to increase cAMP, so activating protein kinase A (PKA) to phosphorylate and activate eNOS resulting in NO release. By contrast, the K+ efflux resulting from A2A-coupled KCa channels facilitates Ca2+ influx, thereby activating eNOS and NO release. This process may be facilitated by phosphorylation of eNOS by PKA via the action of A2A-receptor-mediated stimulation of AC increasing cAMP. These pathways may be important in mediating vasodilatation during exercise and systemic hypoxia when adenosine acting in an endothelium- and NO-dependent manner has been shown to be important.

    Topics: Adenosine; Animals; Aorta, Thoracic; Apamin; Arachidonic Acids; Calcium; Endothelium, Vascular; In Vitro Techniques; Large-Conductance Calcium-Activated Potassium Channels; Male; Nitric Oxide; Peptides; Phospholipases A; Phospholipases A2; Rats; Rats, Wistar; Receptor, Adenosine A1; Receptors, Adenosine A2; Second Messenger Systems; Small-Conductance Calcium-Activated Potassium Channels; Triazines; Triazoles; Vasodilator Agents; Xanthines

2006